Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Predicting the future - big data, machine learning, and clinical medicine
Obermeyer, Z., & Emanuel, E. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606181 · Cited by 3,652
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Kim, H., Zheng, S., Amini, S. S., Virk, S. M., Mikkelsen, T., Brat, D. J., Grimsby, J., Sougnez, C., Muller, F., Hu, J., et al. (2015) · Genome Research · doi:10.1101/gr.180612.114 · Cited by 411
Self-citationOlar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox132 · Cited by 307
Cited by
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
van den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
“20,116,117 The rare absence of TERT promoter mutations in IDH-mutant and 1p/19q-codeleted oligodendro-glioma (occurring in 5% of cases) has been associated with a worse prognosis in one study.”
BackgroundSelf-citationLong-term follow up of patients with WHO grade 2 oligodendroglioma
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04368-6 · Cited by 31
Aboud, O., Shah, R., Vera, E., Burton, E., Theeler, B., Wu, J., Boris, L., Quezado, M., Reyes, J., Wall, K., et al. (2022) · CNS Oncology · doi:10.2217/cns-2021-0005 · Cited by 10
Metadata
- Authors
- Halani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., Olson, J. J., Jiang, T., Yates, J. R., Eberhart, C. G., Poisson, L. M., Cooper, L. A. D., & Brat, D. J.
- Venue
- npj Precision Oncology
- Published
- 2018-11-06
- Volume
- 2
- Issue
- 1
- Pages
- 24-24
- ISSN
- 2397-768X (ISSN-L)
- OpenAlex
- W2896684230
- Cited by
- 50
- References
- 7
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. https://app.cochat.ai/papers/10.1038/s41698-018-0067-9
- The paper
- Halani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., Olson, J. J., Jiang, T., Yates, J. R., Eberhart, C. G., Poisson, L. M., Cooper, L. A. D., & Brat, D. J. (2018). Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. npj Precision Oncology. https://doi.org/10.1038/s41698-018-0067-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.